BioTech IP Review

Assignee: ADC Therapeutics SA
Application Publication: WO 2025083061 A1
Filing Date: October 16, 2024
Publication Date: April 24, 2025
Priority Date: October 17, 2023
Status: Published patent application (pending)

What It Covers

This patent application discloses antibody‑drug conjugates (ADCs) that target the NaPi2b antigen — a membrane protein overexpressed in certain solid tumors (like ovarian and non‑small cell lung cancer). The invention focuses on:

• Antibodies that specifically bind NaPi2b (a sodium‑dependent phosphate transporter) on cancer cells.
• Conjugation of cytotoxic payloads to these antibodies to form ADCs that selectively deliver a potent cancer‑killing drug to NaPi2b‑expressing tumor cells.
• Pharmaceutical compositions and methods of treating cancer with these NaPi2b‑targeting ADCs, including therapeutic dosing regimens and formulations.

The application is part of ADC Therapeutics’ next‑generation ADC efforts expanding beyond its approved product ZYNLONTA® (loncastuximab tesirine‑lpyl) toward additional solid tumor targets.

---

Why This Is Important

Supports pipeline expansion: Targeting NaPi2b expands ADC Therapeutics’ portfolio into heterogeneous solid tumors, a large unmet oncology market beyond CD19‑directed lymphomas.

Anticipated commercial value: If granted, this patent could protect new ADC drug candidates for major cancer indications, enhancing future product value and potentially licensing or collaboration opportunities.

Strategic R&D alignment: The application reflects ADC Therapeutics’ ongoing innovation in ADC design, aligning with its mission of creating potent, targeted cancer therapies.

Industry timing: Publication positions this IP early in the drug development lifecycle, allowing exclusivity to extend well into the 2040s upon grant — a valuable runway for biologic oncology assets.